Risankizumab is under clinical development by AbbVie and currently in Pre-Registration for Ulcerative Colitis. According to GlobalData, Pre-Registration drugs for Ulcerative Colitis have a 96% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Risankizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Risankizumab overview

Risankizumab (Skyrizi) is a humanized monoclonal antibody, acts as an immunosuppressant agent. It is formulated as solution, concentrate solution for subcutaneous and intravenous route of administration. Skyrizi is indicated for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies. Skyrizi is indicated for: the treatment of adult patients with active psoriatic arthritis. Skyrizi can be used alone or in combination with a conventional non-biologic diseasemodifying antirheumatic drug (cDMARD) (e.g., methotrexate). Skyrizi is indicated for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, intolerance, or demonstrated dependence to corticosteroids; or an inadequate response, intolerance, or loss of response to immunomodulators or biologic therapies.

Risankizumab (BI-655066) is under development for the treatment of palmoplantar pustulosis, moderate to severe Crohn's disease, atopic dermatitis, ulcerative colitis and moderate to severe chronic plaque psoriasis with or without psoriatic arthritis, psoriatic erythroderma. BI-655066 is administered through subcutaneous and intravenous route. BI655066 is a humanized IgG1 monoclonal antibody that binds and neutralizes the p19 subunit of IL-23. It was also under development for ankylosing spondylitis.

It was under development for the treatment of moderate to severe hidradenitis suppurativa, asthma and pustular psoriasis.

AbbVie overview

AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, healthcare facilities, government agencies, specialty pharmacies, and independent retailers. The company has operations in the Americas, Asia-Pacific, Europe, the Middle East and Africa. AbbVie is headquartered in North Chicago, Illinois, the US.

For a complete picture of Risankizumab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.